Developing new small molecules to treat Alzheimer's disease
Official title: Development of orally bioavailable and blood-brain barrier penetrant, small molecule TAK1 inhibitors as a novel treatment for Alzheimer's Disease
Funded at Eydis Bio, INC. · NIH-11007130 · Data updated 2026-11-12
This study is looking for new ways to help people with Alzheimer's by testing special tiny molecules that can reach the brain and target a protein called TAK1, which is linked to memory loss and brain cell damage, with the hope of finding better treatments to improve thinking skills and overall well-being.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Eydis Bio, INC. NIH-funded |
| Lab location | 1 site (Durham, United States) |
| Project start | September 15, 2024 |
| Project end | May 31, 2026 |
| Funding year | 2024 |
| Award (this year) | $506,267 |
| NIH project number | 1R41AG090212-01 |
| Project ID | NIH-11007130 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with Alzheimer's disease or those at risk of developing it.
✕Less likely to help
Patients with other forms of dementia or cognitive decline unrelated to Alzheimer's disease may not benefit from this research.
What this research studies
This research focuses on creating small molecule inhibitors that can effectively penetrate the blood-brain barrier to target TAK1, a protein involved in the progression of Alzheimer's disease. By investigating the role of TAK1 in cognitive decline and neuronal death, the research aims to identify new therapeutic options that could slow or prevent the disease's progression. The approach includes using patented TAK1 inhibitors and testing their effectiveness in preclinical models of Alzheimer's. Patients may benefit from new treatment options that could improve their cognitive function and quality of life.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that significantly improve the lives of patients with Alzheimer's disease.
How similar studies have gone: Previous research has shown promise in targeting similar pathways in Alzheimer's disease, indicating potential for success with this novel approach.
Where this research is happening
-
Eydis Bio, INC.
Durham, United States Active
Researchers
- Principal investigator: Scarneo, Scott — Eydis Bio, INC.
- Study coordinator: Scarneo, Scott
Related research
Other NIH-funded projects on the same topics.
-
Understanding how brain activity changes may drive Alzheimer’s disease progression in a mouse model
Researchers are testing how changes in brain signals and protein cleanup processes affect the development of Alzheimer’s disease in mice.
-
Thiamine-boosting therapy for Alzheimer’s: understanding how benfotiamine may reduce harmful AGE in DP patients
A medication-based approach using high-dose vitamin B1 (benfotiamine) is studied to help people with Alzheimer's by reducing harmful sugar-related molecules.
-
Non-invasive tears biomarker for early Alzheimer's in LMICs
A low-cost, tear-based biomarker approach aims to detect early Alzheimer’s disease in older adults in Peru and similar settings.
-
Turning APOE4 into protective APOE2 or APOE3Christchurch to help with Alzheimer’s
A patient-facing explanation of a treatment idea that aims to change a genetic risk factor for Alzheimer's disease in the brain.
-
Telomerase in Alzheimer’s Disease: how aging biology could influence memory and brain health
Researchers are exploring a new brain-aging mechanism linked to telomerase, with potential to slow or modify Alzheimer’s disease in people and improve cognitive function.
-
Biomarkers of Alzheimer’s Disease: Sensory, Motor, and Cognitive Clues
Researchers are testing simple sensory and movement tasks to find early signs of Alzheimer’s disease so they can diagnose and treat people sooner.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.